Onderneming NeuBase Therapeutics, Inc.
Aandelen
NBSE
US64132K2015
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,4396 USD | -0,54% | +2,23% | -40,60% |
Vakgebied
Aantal werknemers: 37
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 10-01-22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 01-11-21 |
Alan Scrivner
LAW | General Counsel | - | 01-09-21 |
Shannon McCarthy
HRO | Human Resources Officer | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 12-07-19 |
Eric Richman
BRD | Director/Board Member | 63 | 12-07-19 |
Director/Board Member | 79 | 12-07-19 | |
Gerald McDougall
BRD | Director/Board Member | 57 | 11-05-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 3 751 590 | 3 249 699 ( 86,62 %) | 0 | 86,62 % |
Bedrijfsgegevens
NeuBase Therapeutics, Inc.
350 Technology Drive Suite 421
15219, Pittsburgh
+
http://www.neubasetherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-40,60% | 1,65 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers NBSE
- Onderneming NeuBase Therapeutics, Inc.